U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07083011) titled 'A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure' on July 16.
Brief Summary: The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Heart Failure With Preserved Ejection Fraction
Intervention:
DRUG: 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
68Ga-FAPI is a gallium-68 fibroblast activation protein inhibitor that will be injected into subjects during a PET (positron emission tomography) scan
Recruitm...